Home > Pulmonology > ATS 2019 > COPD > Benralizumab Does Not Ameliorate COPD Exacerbations (GALATHEA/TERRANOVA trials)

Benralizumab Does Not Ameliorate COPD Exacerbations (GALATHEA/TERRANOVA trials)

Presented By
Prof. Gerard Criner’s, Temple University, USA
Conference
ATS 2019
Trial
Phase 3, GALATHEA, TERRANOVA

New research shows that the asthma drug benralizumab did not statistically decrease annual chronic obstructive pulmonary disease (COPD) exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation; although the team did report numeric decreases. The data were published in the New England Journal of Medicine in conjunction with Prof. Gerard Criner’s (Temple University, USA) presentation [1,2].

The eosinophilic asthma drug benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody which induces rapid and nearly complete eosinophil depletion. COPD is often also associated with eosinophilic inflammation which ultimately affects patients’ responsiveness to glucocorticoid medication. The complementary phase 3, randomised, double-blind, placebo-controlled, parallel-group clinical trials GA...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on